Chaperonins in cancer: Expression, function, and migration in extracellular vesicles

Semin Cancer Biol. 2022 Nov;86(Pt 1):26-35. doi: 10.1016/j.semcancer.2021.05.029. Epub 2021 Jun 1.

Abstract

The chaperonins CCT and Hsp60 are molecular chaperones, members of the chaperone system (CS). Chaperones are cytoprotective but if abnormal in quantity or quality they may cause diseases, the chaperonopathies. Here, recent advances in the understanding of CCT and Hsp60 in cancerology are briefly discussed, focusing on breast and brain cancers. CCT subunits, particularly CCT2, were increased in breast cancer cells and this correlated with tumor progression. Experimental induction of CCT2 increase was accompanied by an increase of CCT3, 4, and 5, providing another evidence for the interconnection between the members of the CS and the difficulties expected while manipulating one member with therapeutic purposes. Another in silico study demonstrated a direct correlation between the increase in the tumor tissue of the mRNA levels of all CCT subunits, except CCTB6, with bad prognosis. Studies with glioblastomas demonstrated an increase in the CCT subunits in the tumor tissue and in extracellular vesicles (EVs) derived from them. Expression levels of CCT1, 2, 6A, and 7 were the most increased and markers of bad prognosis, particularly CCT6A. A method for measuring Hsp60 and related miRNA in exosomes from blood of patients with glioblastomas or other brain tumors was discussed, and the results indicate that the triad Hsp60-related miRNAs-exosomes has potential regarding diagnosis and patient monitoring. All these data provide a strong foundation for future studies on the role played by chaperonins in carcinogenesis and for fully developing their theranostics applications along with exosomes.

Keywords: Brain tumors; Breast cancer; CCT; CCT2; CCT6A; Chaperone system; Chaperonins; Chaperonopathies; Chaperonotherapy; Diagnosis; Exosomes; Extracellular vesicles; Glioblastoma; Hexadecamer; Hsp60; Molecular chaperones; Monomer; Oligomer; Patient monitoring; Personalized treatment; Prognostication; Tetradecamer; miRNA.

Publication types

  • Review

MeSH terms

  • Brain Neoplasms* / metabolism
  • Chaperonin 60 / genetics
  • Chaperonin 60 / metabolism
  • Chaperonin Containing TCP-1 / genetics
  • Chaperonin Containing TCP-1 / metabolism
  • Extracellular Vesicles* / genetics
  • Extracellular Vesicles* / metabolism
  • Glioblastoma* / genetics
  • Glioblastoma* / metabolism
  • Humans
  • MicroRNAs* / genetics
  • Prognosis

Substances

  • Chaperonin Containing TCP-1
  • Chaperonin 60
  • MicroRNAs
  • CCT6A protein, human